[The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer].

Q4 Medicine

Arkhiv patologii Pub Date : 2025-01-01 DOI:10.17116/patol2025870215

A A Studenikina, E D Mangazeeva, A P Bogachuk, V M Lipkin, A I Autenshlyus

{"title":"[The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer].","authors":"A A Studenikina, E D Mangazeeva, A P Bogachuk, V M Lipkin, A I Autenshlyus","doi":"10.17116/patol2025870215","DOIUrl":null,"url":null,"abstract":"The development of drugs with the ability to increase differentiation and reduce tumor malignancy is one of the promising directions in the treatment of breast cancer (BC). As such, Human Leukemia Differentiation Factor (HLDF), a protein consisting of 54 amino acids and contributing to an increase in the degree of differentiation of invasive ductal breast carcinoma cells, can be used. The key disadvantage of the full-size HLDF is its rapid biodegradation. In this connection, the acetylamide form of the peptide (HLDF-6) was synthesized to protect against hydrolysis.Objective: To evaluate the effect of HLDF-6 on cell differentiation in various molecular biological subtypes of breast cancer.Material and methods: The relative content of tumor cells of various degrees of differentiation in biopsies of 33 women with breast cancer when exposed to HLDF-6 tumor was evaluated.Results: HLDF-6 significantly increases the relative content of differentiated cells in the luminal B HER2-negative subtype of breast cancer, without significantly affecting the cells of patients with luminal A and basal-like subtypes.Conclusion: The study revealed the prospects of using HLDF-6 as part of differentiating therapy in patients with luminal B HER2-negative subtype of breast cancer.","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":"87 2","pages":"5-10"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arkhiv patologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/patol2025870215","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The development of drugs with the ability to increase differentiation and reduce tumor malignancy is one of the promising directions in the treatment of breast cancer (BC). As such, Human Leukemia Differentiation Factor (HLDF), a protein consisting of 54 amino acids and contributing to an increase in the degree of differentiation of invasive ductal breast carcinoma cells, can be used. The key disadvantage of the full-size HLDF is its rapid biodegradation. In this connection, the acetylamide form of the peptide (HLDF-6) was synthesized to protect against hydrolysis.

Objective: To evaluate the effect of HLDF-6 on cell differentiation in various molecular biological subtypes of breast cancer.

Material and methods: The relative content of tumor cells of various degrees of differentiation in biopsies of 33 women with breast cancer when exposed to HLDF-6 tumor was evaluated.

Results: HLDF-6 significantly increases the relative content of differentiated cells in the luminal B HER2-negative subtype of breast cancer, without significantly affecting the cells of patients with luminal A and basal-like subtypes.

Conclusion: The study revealed the prospects of using HLDF-6 as part of differentiating therapy in patients with luminal B HER2-negative subtype of breast cancer.

查看原文本刊更多论文

[乙酰酰胺合成肽htlf -6对乳腺癌细胞分化的影响]。

开发具有增强分化和降低肿瘤恶性的药物是乳腺癌治疗的一个有前景的方向。因此，可以使用人类白血病分化因子（HLDF），一种由54个氨基酸组成的蛋白质，有助于增加浸润性导管乳腺癌细胞的分化程度。全尺寸HLDF的主要缺点是它的快速生物降解。在这种情况下，合成了肽的乙酰酰胺形式（HLDF-6）以防止水解。目的：探讨HLDF-6对不同分子生物学亚型乳腺癌细胞分化的影响。材料与方法：评价33例乳腺癌妇女暴露于HLDF-6肿瘤时，活检中不同分化程度肿瘤细胞的相对含量。结果：hbdf -6显著增加了her2阴性乳腺癌腔B亚型中分化细胞的相对含量，而对腔A和基底样亚型患者细胞无显著影响。结论：该研究揭示了将HLDF-6作为luminal B her2阴性亚型乳腺癌患者鉴别治疗的一部分的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arkhiv patologii Medicine-Pathology and Forensic Medicine

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： The journal deals with original investigations on pressing problems of general pathology and pathologic anatomy, newest research methods, major issues of the theory and practice as well as problems of experimental, comparative and geographic pathology. To inform readers latest achievements of Russian and foreign medicine the journal regularly publishes editorial and survey articles, reviews of the most interesting Russian and foreign books on pathologic anatomy, new data on modern methods of investigation (histochemistry, electron microscopy, autoradiography, etc.), about problems of teaching, articles on the history of pathological anatomy development both in Russia and abroad.